Fexofenadine
- Generic Name
- Fexofenadine
- Brand Names
- Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39NO4
- CAS Number
- 83799-24-0
- Unique Ingredient Identifier
- E6582LOH6V
- Background
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to o...
- Indication
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the...
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
- Associated Therapies
- Antihistamine
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00562120
- Locations
- 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 75
- Registration Number
- NCT00420082
- Locations
- 🇦🇹
Allergy Center Vienna West, Vienna, Austria
Fexofenadine in Pruritic Skin Disease
- Conditions
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00261079
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
- Conditions
- First Posted Date
- 2002-09-17
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1000
- Registration Number
- NCT00044824
- Locations
- 🇲🇽
Sanofi-Aventis Administrative Office, Mexico, Mexico
🇨🇷Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica
🇭🇺sanofi-aventis Hungaria, Budapest, Hungary
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
- Conditions
- First Posted Date
- 2002-09-17
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1000
- Registration Number
- NCT00044811
- Locations
- 🇺🇸
Aventis Pharmaceuticals Inc., Bridgewater, New Jersey, United States
🇨🇷Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica
🇷🇺Sanofi-Aventis Administrative Office, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.